PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %
Status:
Recruiting
Trial end date:
2025-12-22
Target enrollment:
Participant gender:
Summary
PERSEE is a French national phase 3 academic study comparing the chemotherapy-pembrolizumab
combination to pembrolizumab alone as a first-line treatment for advanced NSCLC molecularly
defined by a PDL1 expression ≥ 50% of tumour cells and no EGFR mutations or ALK
rearrangement.
The main hypothesis is the superiority of the chemo-immunotherapy combination over
mono-immunotherapy in terms of progression-free survival evaluated by an independent review
committee.
One of the anticipated benefits of using the chemotherapy-pembrolizumab combination starting
from the first line setting for NSCLC patients with PD L1 ≥ 50% is a reduced risk of early
progression, which is known to occur with pembrolizumab monotherapy, and therefore, a better
PFS.